Nintedanib Stada

Nintedanib, the active ingredient in Nintedanib Stada, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. Approved in the European Union, it is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and as part of combination therapy for non‑small cell lung cancer.

GNH USA supplies Nintedanib Stada as a licensed, GDP‑compliant international pharmaceutical supplier, meeting stringent quality standards and serving hospitals, oncology centres, pharmacies and clinics worldwide through reliable logistics and regulatory expertise.

Nintedanib targets fibrotic and oncogenic pathways, providing benefit in several pulmonary and cancer indications.

- Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delay worsening. - Non‑small cell lung cancer (in combination therapy): contributes to tumor growth inhibition when used with other agents.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Abdominal pain - Decreased appetite

Serious or Rare Side Effects: - Liver enzyme elevation leading to hepatitis - Severe bleeding events - Gastrointestinal perforation

When prescribing Nintedanib, clinicians should observe several safety measures to minimize risk.

- Monitor liver function: obtain baseline and periodic ALT/AST assessments. - Assess cardiovascular status: check blood pressure and manage hypertension. - Avoid use in patients with severe hepatic impairment: contraindicated in Child‑Pugh C. - Use caution in patients with bleeding disorders or on anticoagulants: monitor for hemorrhage. - Store at room temperature (below 25°C): keep in the original pack, protect from moisture.

Nintedanib interacts with several drug classes; awareness of these interactions helps avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase Nintedanib exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): decrease Nintedanib exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors (e.g., verapamil): may raise plasma levels modestly. - Proton pump inhibitors: may affect absorption; monitor therapeutic response.